Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DP303c in HER2-expressing advanced ovarian cancer
CTR20210512Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of DP303c in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Mar 2021; status: active.
02
Drugs
DP303c
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20210512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210512.